Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 12/20 | 0.64 |
| ▸ | PREP | P48147 | 2/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997241 | 1.00 | FKBP1A (0.64) | FKBP1APREPKLK5ACEKLK7 | |
| SCHEMBL6787227 | 1.00 | FKBP1A (0.64) | FKBP1APREPKLK5ACEKLK7 | |
| SCHEMBL7295710 | 0.92 | PREP (0.62) | FKBP1APREPKLK5ACEKLK7 | |
| SCHEMBL2082597 | 0.89 | PREP (0.69) | FKBP1APREPACE | |
| SCHEMBL6605416 | 0.87 | FKBP1A (0.49) | FKBP1APREPKLK5 | |
| SCHEMBL31049706 | 0.85 | ADORA3 (0.57) | FKBP1APREPKLK5ACECTSL | |
| SCHEMBL9464405 | 0.85 | PREP (0.67) | FKBP1APREPKLK5ACE | |
| SCHEMBL18620837 | 0.85 | PREP (0.67) | FKBP1APREPKLK5ACE | |
| SCHEMBL159105 | 0.84 | KLK7 (0.66) | FKBP1APREPKLK5KLK7 | |
| SCHEMBL5970730 | 0.84 | KLK7 (0.66) | FKBP1APREPKLK5KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684727-A | GPRP series peptide modified dabigatran derivative, synthesis, activity and application thereof | 首都医科大学 | 2024-09-24 | — | — | CN | claimed |
| CN-118620088-A | Trimer of Asn-Gly-Pro, preparation and application thereof | 首都医科大学 | 2024-09-10 | — | — | CN | claimed |
| US-12528834-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2026-01-20 | — | — | US | disclosed |
| CN-118684727-A | GPRP series peptide modified dabigatran derivative, synthesis, activity and application thereof | 首都医科大学 | 2024-09-24 | — | — | CN | disclosed |
| CN-118620088-A | Trimer of Asn-Gly-Pro, preparation and application thereof | 首都医科大学 | 2024-09-10 | — | — | CN | disclosed |
| CN-113929735-B | Gly-Pro-Arg-Pro-NHCH 2 CH 2 NH-warfarin, its synthesis, activity and use | 首都医科大学 | 2023-08-01 | — | — | CN | disclosed |
| US-20220372069-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-11-24 | — | — | US | disclosed |
| EP-4036103-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | Nissan Chemical Corporation (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-114401978-A | Method for producing peptide compound | 日产化学株式会社 | 2022-04-26 | — | — | CN | disclosed |
| CN-109111502-B | 1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-GGPRP, and synthesis, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
| WO-2021060048-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | 日産化学株式会社 | 2021-04-01 | — | — | WO | disclosed |
| US-8362068-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-4971993-A | HYPOTENSIVE DIPEPTIDES DERIVATIVES | AJINOMOTO CO., INC. (JP) | 1990-11-20 | — | — | US | disclosed |
| EP-0190852-A2 | Dipeptide derivatives and antihypertensive drugs containing them | AJINOMOTO CO., INC. (JP) | 1986-08-13 | — | — | EP | disclosed |
| US-4590178-A | DIURETICS | AJINOMOTO COMPANY, INCORPORATED (JP) | 1986-05-20 | — | — | US | disclosed |
| US-4536395-A | DIPEPTIDES | AJINOMOTO CO., INC. (JP) | 1985-08-20 | — | — | US | disclosed |
| US-4472381-A | Amino acid derivatives, methods of preparing said derivatives and antihypertensive drugs containing them | AJINOMOTO COMPANY INCORPORATED (JP) | 1984-09-18 | — | — | US | disclosed |
| EP-0085488-A2 | Amino acid derivatives and antihypertensive drugs containing them | AJINOMOTO CO., INC. (JP) | 1983-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | FKBP1A 1317/4885PREP 1133/4885KLK5 2911/4885 |
| US-12528834-B2 | Method for producing peptide compound | VIP, IAPP, NPPA | FKBP1A 2713/4885PREP 91/4885KLK5 1202/4885 |
| US-20220372069-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, NPPA, NGLY1 | FKBP1A 1695/4885PREP 31/4885KLK5 1690/4885 |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | HAVCR2, CYP3A5, CYP7A1 | FKBP1A 895/4885PREP 663/4885KLK5 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.